新型腺病毒载体肺结核疫苗的免疫原性研究  

Immunogenicity study of novel Ad5 based tuberculosis vaccine

作　　者：史晓雨 隋秀文 苗伟 高德进 王畅 魏梦函 朱涛(指导)[1] SHI Xiao-Yu;SUI Xiu-Wen;MIAO Wei;GAO De-Jin;WANG Chang;WEI Meng-Han;ZHU Tao(Tianjin University of Science & Technology,Tianjin 300457,China)

机构地区：[1]天津科技大学,天津300457 [2]康希诺生物股份公司,天津300457

出　　处：《中国免疫学杂志》2020年第6期719-722,共4页Chinese Journal of Immunology

基　　金：国家科技重大专项项目(2018ZX10731301-001-002)。

摘　　要：目的:评价双价肺结核疫苗的免疫原性。方法:ESAT6、rv3407、RpfB三种抗原基因融合后(TPA-3Ag)与Ag85A一种抗原基因均用重组人5型腺病毒载体进行表达,按照1∶0.2、1∶1、1∶2、1∶4四种不同滴度配比免疫小鼠。使用酶联免疫吸附实验(ELISA)进行抗原特异性体液免疫评价,使用酶联免疫斑点法(ELISpot)和细胞内细胞因子染色(ICS)进行抗原特异性细胞免疫评价。结果:双价疫苗均产生体液免疫应答和细胞免疫应答。结论:双价疫苗有提高肺结核保护范围的可能性,可能成为预防结核病的新型疫苗。Objective:To evaluate the immunogenicity of bivalent tuberculosis vaccine.Methods:ESAT6,rv3407 and RpfB three antigen gene fusion(TPA-3Ag)and Ag85A an antigen gene were expressed by recombinant human type 5 adenovirus vector,according to 1∶0.2,1∶1,1∶2 and 1∶4 four different titer ratios to immunize mice.Antigen-specific humoral immunoassay using enzyme-linked immunosorbent assay(ELISA),antigen-specific cellular immune evaluation using enzyme-linked immunospot assay(ELISpot)and intracellular cytokine staining(ICS).Results:Bivalent vaccines produce both humoral and cellular immune responses.Conclusion:Bivalent vaccine have the potential to increase the scope of tuberculosis protection and may become a new vaccine against tuberculosis.

关 键 词：人5型腺病毒 ESAT6 rv3407 RpfB AG85A 肺结核 

分 类 号：R183.3[医药卫生—流行病学]